Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis

Brain Research

Volumn 1239, Issue , 2008, Pages 216-225

  Zhang, Ran ^a   Banik, Naren L ^a   Ray, Swapan K ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cytochrome c; Glioblastoma; PTEN; Taxol; VEGF

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA ACTIN; CASPASE; CYTOCHROME C; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; STAINING; UPREGULATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MITOCHONDRIA; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53949100236     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.08.075     Document Type: Article

References (50)

1. Abe T., Terada K., Wakimoto H., Inoue R., Tyminski E., Bookstein R., Basilion J.P., and Chiocca E.A. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 63 (2003) 2300-2305
2. Adams J.M., and Cory S. The Bcl-2 protein family: arbiters of cell survivals. Science 281 (1998) 1322-1326
3. Bello L., Giussani C., Carrabba G., Pluderi M., Costa F., and Bikfalvi A. Angiogenesis and invasion in gliomas. Cancer Treat. Res. 117 (2004) 263-284
4. Cahan M.A., Walter K.A., Colvin O.M., and Brem H. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother. Pharmacol. 33 (1994) 441-444
5. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P.S., Mellinghoff I.K., and Sawyers C.L. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5 (2008) e8
6. Das A., Banik N.L., and Ray S.K. Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. Int. J. Cancer. 119 (2006) 2575-2585
7. Das A., Banik N.L., and Ray S.K. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J. Neurooncol. 87 (2008) 9-22
8. Edwards L.A., Woo J., Huxham L.A., Verreault M., Dragowska W.H., Chiu G., Rajput A., Kyle A.H., Kalra J., Yapp D., Yan H., Minchinton A.I., Huntsman D., Daynard T., Waterhouse D.N., Thiessen B., Dedhar S., and Bally M.B. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol. Cancer Ther. 7 (2008) 59-70
9. Fan X., Aalto Y., Sanko S.G., Knuutila S., Klatzmann D., and Castresana J.S. Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas. Int. J. Oncol. 21 (2002) 1141-1150
10. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhänel M., Spruss T., Bernhardt G., Graeff C., Färber L., Gschaidmeier H., Buschauer A., and Fricker G. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 110 (2002) 1309-1318
11. Fischer I., Gagner J.P., Law M., Newcomb E.W., and Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 15 (2005) 297-310
12. Fisher T., Galanti G., Lavie G., Jacob-Hirsch J., Kventsel I., Zeligson S., Winkler R., Simon A.J., Amariglio N., Rechavi G., and Toren A. Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. Cancer J. 13 (2007) 335-344
13. Gagandeep S., Novikoff P.M., Ott M., and Gupta S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett. 136 (1999) 109-118
14. Gan Y., Wientjes M.G., and Au J.L. Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin. Cancer Res. 4 (1998) 2949-2955
15. Geney R., Chen J., and Ojima I. Recent advances in the new generation taxane anticancer agents. Med. Chem. 1 (2005) 125-139
16. Glantz M.J., Chamberlain M.C., Chang S.M., Prados M.D., and Cole B.F. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin. Radiat. Oncol. 9 (1999) 27-33
17. Gligorov J., and Lotz J.P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 Suppl. 2 (2004) 3-8
18. Gomez-Manzano C., Fueyo J., Jiang H., Glass T.L., Lee H.Y., Hu M., Liu J.L., Jasti S.L., Liu T.J., Conrad C.A., and Yung W.K. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann. Neurol. 53 (2003) 109-117
19. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
20. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005) 997-1003
21. Huang F., Kavan P., Guiot M.C., Markovic Y., and Roberge D. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma. Can. J. Neurol. Sci. 35 (2008) 192-197
22. Jiang Z., Pore N., Cerniglia G.J., Mick R., Georgescu M.M., Bernhard E.J., Hahn S.M., Gupta A.K., and Maity A. Phosphate and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res. 67 (2007) 4467-44473
23. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
24. Kargiotis O., Rao J.S., and Kyritsis A.P. Mechanisms of angiogenesis in gliomas. J. Neurooncol. 78 (2006) 281-293
25. Karmakar S., Banik N.L., and Ray S.K. Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer 112 (2008) 596-607
26. Kaur B., Tan C., Brat D.J., Post D.E., and Van Meir E.G. Genetic and hypoxic regulation of angiogenesis in gliomas. J. Neurooncol. 70 (2004) 229-243
27. Kleihues P., and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology 1 (1999) 44-51
28. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control Release 99 (2004) 259-269
29. Maity A., Pore N., Lee J., Solomon D., and O'Rourke D.M. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res. 60 (2000) 5879-5886
30. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., Maclennan S., Baraldi P.G., and Borea P.A. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol. Pharmacol. 72 (2007) 162-172
31. Ohgaki H., and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170 (2007) 1445-1453
32. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15 (2004) 171-176
33. Piqué M., Barragán M., Dalmau M., Bellosillo B., Pons G., and Gil J. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett. 480 (2000) 193-196
34. Pore N., Lius A., Haas-Kogan D.A., O'Rourke D.M., and Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 63 (2003) 236-241
35. Ray S.K., Wilford G.G., Crosby C.V., Hogan E.L., and Banik N.L. Diverse stimuli induce calpain overexpression and apoptosis in C6 glioma cells. Brain Res. 829 (1999) 18-27
36. Ray S.K., Patel S.J., Welsh C.T., Wilford G.G., Hogan E.L., and Banik N.L. Molecular evidence of apoptotic death in malignant brain tumors including glioblastoma multiforme: upregulation of calpain and caspase-3. J. Neurosci. Res. 69 (2002) 197-206
37. Ray S.K., Karmakar S., Nowak M.W., and Banik N.L. Inhibition of calpain and caspase-3 prevented apoptosis and preserved electrophysiological properties of voltage-gated and ligand-gated ion channels in rat primary cortical neurons exposed to glutamate. Neuroscience 139 (2006) 577-595
38. Reardon D.A., Desjardins A., Rich J.N., and Vredenburgh J.J. The emerging role of anti-angiogenic therapy for malignant glioma. Curr. Treat. Options Oncol. 9 (2008) 1-22
39. Rong Y., Post D.E., Pieper R.O., Durden D.L., Van Meir E.G., and Brat D.J. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65 (2005) 1406-1413
40. Rose W.C. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3 (1992) 311-321
41. Rosenthal M.A., Gruber M.L., Glass J., Nirenberg A., Finlay J., Hochster H., and Muggia F.M. Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 47 (2000) 59-63
42. Sano T., Lin H., Chen X., Langford L.A., Koul D., Bondy M.L., Hess K.R., Myers J.N., Hong Y.K., Yung W.K., and Steck P.A. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 59 (1999) 1820-1824
43. Son M.J., Song H.S., Kim M.H., Kim J.T., Kang C.M., Jeon J.W., Park S.Y., Kim Y.J., Groves M.D., Park K., Kim J.H., and Nam D.H. Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma. Int. J. Oncol. 28 (2006) 1385-1392
44. Steiner H.H., Karcher S., Mueller M.M., Nalbantis E., Kunze S., and Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J. Neurooncol. 66 (2004) 129-138
45. Utsunomiya H., Akahira J., Tanno S., Moriya T., Toyoshima M., Niikura H., Ito K., Morimura Y., Watanabe Y., and Yaegashi N. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int. J. Gynecol. Cancer 16 (2006) 52-56
46. Veltkamp S.A., Rosing H., Huitema A.D., Fetell M.R., Nol A., Beijnen J.H., and Schellens J.H. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. Cancer Chemother. Pharmacol. 60 (2007) 635-642
47. Wen S., Stolarov J., Myers M.P., Su J.D., Wigler M.H., Tonks N.K., and Durden D.L. PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4622-4627
48. Yang S.H., Kim M.K., Lee T.K., Lee K.S., Jeun S.S., Park C.K., Kang J.K., Kim M.C., and Hong Y.K. Temozolomide chemotherapy in patients with recurrent malignant gliomas. J. Korean Med. Sci. 21 (2006) 739-744
49. Zhang R., Banik N.L., and Ray S.K. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-κB survival signaling in glioblastoma U87MG cells for induction of apoptosis. Neurochem. Res. 32 (2007) 2194-2202
50. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D., and Giaccia A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14 (2000) 391-396